Evotec Wins Research Grant to Advance H3 Receptor Antagonist Programme into the Clinic
(Thomson Reuters ONE) -
Evotec AG / Evotec Wins Research Grant to Advance H3 Receptor Antagonist Programme into the Clinic processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
Hamburg, Germany - 27 April 2010: Evotec AG (Frankfurt Stock Ex-change: EVT,
TecDAX) today announced that it will receive funding of up to EUR 1.5 million
from the German Federal Ministry of Education and Research (BMBF) to advance its
H3 receptor antagonist programme into the clinic.
Using its CNS expertise coupled with its world leading discovery platform Evotec
has successfully identified and optimised H3 receptor antagonists through to
preclinical development. This grant will now provide external funding for Evotec
to advance the programme through Phase I clinical studies.
The histamine H3 receptor is a drug target of high interest because of evidence
that blocking this receptor in the brain can improve cognition, alertness and
attention. H3 receptor antagonists therefore have the potential to become an
important new class of therapy in a number of CNS indications, including
excessive fatigue associated with conditions such as multiple sclerosis.
Dr Werner Lanthaler, Chief Executive Officer of Evotec commented: "We are happy
that the Neu² consortium has chosen to support our H3 receptor antagonist
programme for further development within the BioPharma initiative. By driving
these novel drug candidates from identification through to the first clinical
steps, we can optimally capture the commercial value of this programme."
Contact: Dr Werner Lanthaler, Chief Executive Officer,
Evotec AG, Tel.: +49.(0)40.56081-242, werner.lanthaler(at)evotec.com
Forward-looking statements
Information set forth in this press release contains forward-looking statements,
which involve a number of risks and uncertainties.Such forward-looking
statements include, but are not limited to, statements about our financial
outlook for 2010 and beyond; our expectation that our current cash, cash
equivalents, investments, and operating revenues will be sufficient to fund our
planned activities beyond 2012, and our belief that we are on course to
profitability and sustainability by 2012; our expectations regarding the growth
of the pharmaceutical outsourcing drug discovery market, the opportunities such
growth will provide us, and our ability to take advantage of such market
developments and become a leader in this industry in the coming years; our
expectations regarding the impacts, and anticipated timing of such impacts, of
the "Evotec 2012 - Action Plan to Focus and Grow"; our expectation that our
reentry into the German technology TecDAX in 2009 will increase liquidity for
our shareholders and that our voluntary delisting from NASDAQ and anticipated
de-registration with the SEC will streamline our activities and focus the
liquidity of Evotec's stock on one trading platform; our expectations regarding
the impact that the recent global financial crisis will have on our company; our
expectations and assumptions concerning regulatory, clinical, and business
strategies, the progress of our clinical development programmes and timing of
the results of our clinical trials, strategic collaborations, and management's
plans, objectives and strategies. These statements are neither promises nor
guarantees, but are subject to a variety of risks and uncertainties, many of
which are beyond our control, and which could cause actual results to differ
materially from those contemplated in these forward-looking statements. In
particular, the risks and uncertainties include, among other things: risks that
we may be unable to achieve the anticipated benefits of our revised business
focus, restructuring, and cost containment measures or recognise the results of
such measures within the expected timeframes; risks that we will not achieve the
anticipated benefits of our collaborations, partnerships and acquisitions in the
timeframes expected, or at all; the risk that we will not achieve the
anticipated benefits of our voluntarily delisting from NASDAQ and anticipated
de-registration from the SEC; risks that product candidates may fail in the
clinic or may not be successfully marketed or manufactured; risks relating to
our ability to advance the development of product candidates currently in the
pipeline or in clinical trials; our inability to further identify, develop and
achieve commercial success for new products and technologies; the risk that
competing products may be more successful; our inability to interest potential
partners in our technologies and products; our inability to achieve commercial
success for our products and technologies; our inability to protect our
intellectual property and the cost of enforcing or defending our intellectual
property rights; our failure to comply with regulations relating to our products
and product candidates, including FDA requirements; the risk that the FDA may
interpret the results of our studies differently than we have; the risk that
clinical trials may not result in marketable products; the risk that we may be
unable to successfully secure regulatory approval of and market our drug
candidates; risks of new, changing and competitive technologies and regulations
in the U.S. and internationally; general worldwide economic conditions and
related uncertainties; future legislative, regulatory, or tax changes as well as
other economic, business and/or competitive factors; and the effect of exchange
rate fluctuations on our international operations.
The list of risks above is not exhaustive. Our Annual Report on Form 20-F most
recently filed with the Securities and Exchange Commission, and other filings
and items furnished with the Securities and Exchange Commission, contain
additional factors that could impact our businesses and financial performance.
We expressly disclaim any obligation or undertaking to release publicly any
updates or revisions to any such statements to reflect any change in our
expectations or any change in events, conditions or circumstances on which any
such statement is based.
[HUG#1408478]
--- End of Message ---
Evotec AG
Schnackenburgallee 114 Hamburg Germany
WKN: 566480;ISIN: DE0005664809;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
Pdf of PressRelease: http://hugin.info/131215/R/1408478/361227.pdf
Unternehmensinformation / Kurzprofil:
Datum: 27.04.2010 - 07:58 Uhr
Sprache: Deutsch
News-ID 19714
Anzahl Zeichen: 0
contact information:
Town:
Hamburg
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 323 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Evotec Wins Research Grant to Advance H3 Receptor Antagonist Programme into the Clinic"
steht unter der journalistisch-redaktionellen Verantwortung von
Evotec AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
